Teva Pharmaceutical Industries Ltd.
Israeli pharmaceutical company
TEVA Tel Aviv Stock Exchange · home listing
Tel Aviv Stock Exchange
TEVA NYSE
ISIN IL0006290147 SEC CIK 818686 LEI 549300BAFGM4RC74ZJ94
Follow Teva Pharmaceutical Industries Ltd.
Weekly email: filings, results
Revenue, last quarter
$4.4B
−1.9% vs same quarter last year
Net income
$233M
−46.2% vs same quarter last year
EPS, diluted
$0.20
−45.9% vs same quarter last year
Operating cash flow
$241M
−34.7% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $17.3B | $1.4B |
| FY24 | $16.5B | −$1.6B |
| FY23 | $15.8B | −$559M |
| FY22 | $14.9B | −$2.4B |
| FY21 | $15.9B | $417M |
| FY20 | $16.7B | −$4B |
| FY19 | $16.9B | −$999M |
| FY18 | $18.3B | −$2.2B |
| FY17 | $21.9B | −$16.3B |
| FY16 | $21.9B | $329M |
| FY15 | $19.7B | $1.6B |
| FY14 | $20.3B | $3.1B |
| FY13 | $20.3B | $1.3B |
| FY12 | $20.3B | $2B |
| FY11 | $18.3B | $2.8B |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 51.8% | 12.5% | 8.2% |
| FY24 | 48.7% | −1.8% | −9.9% |
| FY23 | 48.2% | 2.7% | −3.5% |
| FY22 | 46.7% | −14.7% | −16.4% |
| FY21 | 47.8% | 10.8% | 2.6% |
| FY20 | 46.4% | −21.4% | −24% |
| FY19 | 44.6% | −2.6% | −5.9% |
| FY18 | 45.4% | −9% | −11.8% |
| FY17 | 48.6% | −80% | −74.4% |
| FY16 | 53.2% | 9.8% | 1.5% |
| FY15 | 57.8% | 17.1% | 8.1% |
| FY14 | 54.5% | 19.5% | 15.1% |
| FY13 | 52.7% | 8.1% | 6.2% |
| FY12 | 52.4% | 10.9% | 9.7% |
| FY11 | 52% | 17% | 15.1% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | $1.1B |
| FY24 | $749M |
| FY23 | $842M |
| FY22 | $1B |
| FY21 | $236M |
| FY20 | $638M |
| FY19 | $223M |
| FY18 | $1.8B |
| FY17 | $1.4B |
| FY16 | $3B |
| FY15 | $4.8B |
| FY14 | $4.2B |
| FY13 | $2.2B |
| FY12 | $3.5B |
| FY11 | $3.1B |
- Dividends
- Buybacks
Show the numbers
| Year | Dividends | Buybacks |
|---|---|---|
| FY25 | - | - |
| FY24 | - | - |
| FY23 | - | - |
| FY22 | - | - |
| FY21 | - | - |
| FY20 | - | - |
| FY19 | - | - |
| FY18 | $12M | - |
| FY17 | $901M | $0 |
| FY16 | $1.3B | $0 |
| FY15 | $1.2B | $439M |
| FY14 | $1.2B | $500M |
| FY13 | $1.1B | $497M |
| FY12 | $855M | $1.2B |
| FY11 | $800M | $899M |
- Teva Pharmaceutical Industries Ltd.
- Healthcare median
Show the numbers
| Year | Teva Pharmaceutical Industries Ltd. | Healthcare median |
|---|---|---|
| FY25 | 8.2% | −30.6% |
| FY24 | −9.9% | −47% |
| FY23 | −3.5% | −58% |
| FY22 | −16.4% | −80.4% |
| FY21 | 2.6% | −71.9% |
| FY20 | −24% | −62.2% |
| FY19 | −5.9% | −46.3% |
| FY18 | −11.8% | −49.6% |
| FY17 | −74.4% | −45.9% |
| FY16 | 1.5% | −36% |
| FY15 | 8.1% | −38.4% |
| FY14 | 15.1% | −35.5% |
| FY13 | 6.2% | −37.1% |
| FY12 | 9.7% | −29.1% |
| FY11 | 15.1% | −27.9% |